Jeuveau (also known as Nabota) 100 IU is a high-purity botulinum toxin type A formulated for the temporary improvement of dynamic facial wrinkles. Manufactured using Hi-Pure™ purification technology, it features a highly refined neurotoxin complex with low protein load, enabling predictable onset, consistent diffusion, and reliable clinical outcomes.
The product is commonly used for glabellar lines, horizontal forehead lines, crow's feet, and advanced aesthetic applications such as masseter reduction, bunny lines, and lip flip, when performed by experienced practitioners.Clinical onset typically occurs within 2-4 days, with full effect at 7-10 days, and duration of action lasting 3-4 months, depending on muscle strength and dose.
Product data
Active substance: Clostridium botulinum toxin type A
Potency: 100 units per vial
Purity: High-purity toxin using Hi-Pure™ technology
Excipients: Human serum albumin, sodium chloride
Form: Vacuum-dried powder for reconstitution
Packaging: 1 vial (Korean domestic packaging)
Dosage & tools
Reconstitution:Mix 100 IU with 2.5 ml of sterile 0.9% saline → 4 IU per 0.1 ml(Other dilutions-1.25 ml, 2 ml, 4 ml-may be used based on practitioner technique.)
Typical aesthetic dosing:
Glabellar lines: 20 IU
Forehead lines: 10-20 IU
Crow's feet: 12-24 IU
Masseter hypertrophy: 25-30 IU per side
Bunny lines: 4-8 IU
DAO: 4-6 IU
Lip flip: 4-6 IU
Recommended instruments:
30G-32G needle for intramuscular delivery
Inject under strict aseptic protocol
Aspirate when indicated; inject slowly
Treatment must only be performed by clinicians trained in botulinum toxin administration.
Storage & handling
Store unopened vials at 2 °C - 8 °C (refrigerated)
Use reconstituted solution immediately
Do not freeze the dry toxin or reconstituted product
Single-use vial - discard all unused material
Dispose of needles and syringes according to medical waste regulations
Intended for use by licensed medical professionals only
Administer intramuscular injections using established anatomical mapping and individualized dosing per muscle strength and treatment goals. Reconstitute and inject according to manufacturer instructions; distribute units across standardized points to optimize symmetry and effect. For safety, avoid intravascular injection, inject slowly, and adhere to aseptic technique. Professional use only.
Advise patients to avoid alcohol for at least 24 hours before and after treatment to limit vasodilation-related bruising and swelling and to support optimal recovery.
Not recommended in pregnancy. Controlled safety data are lacking, and systemic exposure risks cannot be excluded. Elective aesthetic procedures should be postponed until after delivery.
Botulinum Toxin Type A (prabotulinumtoxinA) in a lyophilized powder for reconstitution; formulated for reliable diffusion characteristics and predictable aesthetic outcomes when used by qualified clinicians.
Common: transient injection-site pain, redness, swelling, bruising, headache, or localized tenderness (typically resolving within several days). Rare but serious: eyelid/brow ptosis, asymmetry, diplopia; hypersensitivity reactions; and symptoms suggestive of toxin spread (e.g., dysphagia, dysphonia, breathing difficulty). These require immediate medical evaluation. Post-procedure, avoid rubbing or massaging treated areas and follow provider aftercare.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNARE proteins (e.g., SNAP-25), producing a reversible chemodenervation of the targeted muscles and a visible reduction in dynamic lines. Function gradually returns as neuromuscular signaling is restored.
Not advised while breastfeeding due to insufficient data on toxin/metabolite transfer into breast milk and potential infant risk. Defer treatment until breastfeeding has concluded.
